# Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer

> **NCT02632045** · PHASE2 · COMPLETED · sponsor: **Melissa K Accordino** · enrollment: 169 (actual)

## Conditions studied

- Metastatic Breast Cancer
- Breast Carcinoma

## Interventions

- **DRUG:** LEE-011
- **DRUG:** Fulvestrant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02632045
- **Lead sponsor:** Melissa K Accordino
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2022-01-04
- **Final completion:** 2022-01-04
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2024-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02632045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02632045, "Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02632045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*